Core Insights - China is leveraging policy advantages, deep involvement of tech giants, and a large user base to showcase its technological edge in the global healthcare AI arena [1][3] - The rapid development of healthcare AI in China is significantly supported by strong policy guidance, which has provided a clear growth path for the industry [1][3] Industry Overview - By 2024, approximately 400 million people in China are expected to use digital healthcare services, with over 800 million users linking their basic medical insurance information to Alipay [3] - The Chinese online healthcare market is projected to reach 480 billion RMB (approximately 69 billion USD) by 2025 [3] Company Highlights - Ant Group's AI health assistant "Ant Aifu" has attracted over 1,000 licensed doctors to train its digital avatars, demonstrating significant engagement and utility [3] - In the past year, AI avatars managed over 27 million inquiries, with "Ant Aifu" currently having around 30 million active users and processing approximately 10 million health consultations daily [3] - Alibaba Health is expected to achieve over 60% profit growth in 2024, indicating the commercial viability of the "AI + healthcare" model [3] Competitive Landscape - Despite its leading position, the healthcare AI sector in China faces intense competition from established companies like Tencent, DeepSeek, and Ping An Medical Technology [4] - Continuous innovation is essential for maintaining competitive advantages in this rapidly evolving market [4]

Core Insights - The article highlights the rapid growth and impact of Ant Group's health AI application "Antifufu," which has reached 30 million monthly active users and 10 million daily consultations, indicating strong demand in the healthcare sector [2] - Antifufu embodies Jack Ma's philosophy of "using technology to solve social problems" by connecting 5,000 hospitals and 300,000 real doctors, enabling medical services to reach rural areas through mobile devices [2] Group 1 - The article features interviews with two doctors who have established "AI avatars" on Antifufu, showcasing how AI can enhance healthcare access in remote areas [3] - A liver specialist in Qinghai uses his AI avatar to assist herders with post-consultation questions, reducing the need for long travel to see a doctor [3] - A gynecologist in Shanghai has seen over 160,000 consultations through his AI avatar, emphasizing the suitability of AI for addressing common patient inquiries during pregnancy [3] Group 2 - Ant Group aims to replicate its success in mobile payments and financial inclusion within the healthcare sector, having established a foothold in online appointment booking and digital health insurance services over a decade ago [5] - Over 800 million users have activated electronic health insurance codes on Alipay, allowing patients to access healthcare without physical documents [5] - The macro environment in China is becoming more favorable for digital health services, with government policies supporting the widespread application of medical AI and encouraging data sharing [5] Group 3 - Alibaba Health has turned profitable after years of losses, with profit growth exceeding 60% since 2024, validating Jack Ma's long-term vision for health as a key area of focus [5] - Jack Ma's "Double H" strategy, emphasizing Health and Happiness, continues to guide the development of both Ant Group and Alibaba despite his reduced involvement in company management [6]

Market Overview - The Hong Kong stock market experienced a rise followed by a slight retreat, with the Hang Seng Index closing at 27,183.15 points, up 0.58% or 155.99 points, and a total trading volume of 234.04 billion HKD [1] - The Hang Seng China Enterprises Index increased by 0.81% to 9,242.75 points, while the Hang Seng Tech Index rose by 0.62% to 5,451.03 points [1] Blue-Chip Stocks Performance - Pop Mart (09992) continued its upward trend, closing up 4.9% at 269.8 HKD, contributing 14.96 points to the Hang Seng Index [2] - Other notable blue-chip stocks included CSPC Pharmaceutical Group (01093) up 5.52% at 10.32 HKD, and Innovent Biologics (01801) up 4.98% at 89.65 HKD [2] - New Oriental Education (09901) fell by 4.39% to 46.66 HKD, negatively impacting the index by 2.61 points [2] Sector Highlights - The biotechnology sector showed strong performance, with CSPC Pharmaceutical Group (01093) up 5.52%, and Innovent Biologics (01801) up 4.98% [3] - AI-related stocks surged, with WeMedia Group (00772) rising 15.41% and Zhizhu (02513) increasing by 14.81% [4] - The energy sector saw significant movements, with Dongfang Electric (01072) up 7.11% and Harbin Electric (01133) up 4.51% due to ongoing electricity shortages in North America [6] Investment Opportunities - The global strategic cooperation between Innovent Biologics and Eli Lilly could lead to a potential transaction value of up to 8.85 billion USD, indicating a strong start for business development in 2026 [4] - The AI computing power center project by Ruifeng New Energy (00527) in Zhangjiakou, with a total investment of approximately 24 billion RMB, is expected to enhance the region's technological capabilities [8] Notable Stock Movements - Lexin Outdoor (02720) saw its stock price double on its first trading day, closing up 102.29% at 24.78 HKD [7] - Jiuzhou Intelligent Investment Holdings (09636) issued a profit warning, projecting revenue of approximately 3.43 billion RMB for 2025, an increase of about 1.12 billion RMB from the previous year [10] - Changfei Optical Fiber (06869) reached a new high, closing up 8.88% at 114 HKD, driven by rising fiber prices due to supply-demand imbalances [11]

Group 1 - The number of mainland private equity fund managers holding Hong Kong's Type 9 license has exceeded 130, marking an increase of over 40 compared to the same period last year, indicating a significant trend towards internationalization among mainland private equity firms [1] - As of November 2025, the total number of mainland private equity institutions holding the Type 9 license reached 107, and this number quickly rose to 135, reflecting a strong demand for global asset allocation among leading private equity firms [1] - Holding a Type 9 license signifies that these private equity firms have obtained legal qualifications to conduct regulated asset management business in Hong Kong, which plays a crucial role in enhancing the international competitiveness of Chinese private equity [1] Group 2 - The Hong Kong IPO market has been thriving, with institutional investors participating in cornerstone investments exceeding 30 billion HKD since the beginning of the year, including significant contributions from major mainland private equity firms and international funds [2] - Foreign institutions have made multiple increases in holdings in the Hong Kong stock market since 2026, with Morgan Stanley investing over 1 billion HKD in several listed companies, indicating that Hong Kong remains a key entry point for foreign capital into China [2] - The internationalization of mainland private equity is transitioning from a trial phase to a new cycle of global competition, with the growing number of licensed private equity firms signaling a new stage of high-quality development in the Chinese private equity industry [2]

Core Viewpoint - The Hong Kong stock market showed strong performance in the healthcare sector, particularly in innovative drugs and medical companies, with significant gains observed in various stocks [1] Group 1: Market Performance - The Hong Kong stock market experienced fluctuations but ultimately strengthened, with notable performances in the innovative drug and medical sectors [1] - Stocks such as CSPC Pharmaceutical Group and Innovent Biologics rose over 6%, while others like Zai Lab and WuXi Biologics increased by more than 5% [1] - The Hong Kong Stock Connect Medical ETF (159506) saw a rise of over 3% during trading [1] Group 2: Industry Insights - At the J.P. Morgan Healthcare Conference held in January, global pharmaceutical companies disclosed advanced research pipelines and significant business development transactions, creating clear order expectations for the CXO industry [1] - The penetration of AI in healthcare is accelerating, with applications expanding from smart consultations to chronic disease management, leading to a reevaluation of the value of internet healthcare platforms like Alibaba Health and JD Health [1] - Analysts suggest that the current healthcare sector presents multiple investment opportunities, with the CXO industry benefiting from a recovery in overseas orders and domestic capacity clearance [1] - The medical device sector is supported by domestic equipment upgrade policies and overseas market expansion, with cutting-edge areas like brain-computer interfaces and AI imaging continuously catalyzing growth [1] - Internet healthcare is optimizing operational efficiency against the backdrop of deepening medical insurance payment reforms, leading to a clearer profitability growth trajectory [1] Group 3: ETF Information - The Hong Kong Stock Connect Medical ETF (159506) closely tracks the Hang Seng Hong Kong Stock Connect Innovative Drug and Healthcare Index (HSSCHI) [2] - The index composition emphasizes companies with high R&D expenditure and innovative drug business, ensuring that companies with the lowest average R&D to revenue ratio over the past two years are excluded [2] - This innovative focus aids investors in accurately capturing investment opportunities within the Hong Kong pharmaceutical sector [2]

Group 1 - The core point of the article highlights that southbound funds increased their holdings in Alibaba Health (00241.HK) by 11.662 million shares on February 9 [1] - Over the past five trading days, there were two days of net reductions in holdings by southbound funds, totaling a net decrease of 15.941 million shares [1] - In the last 20 trading days, there were 13 days of net increases in holdings by southbound funds, with a total net increase of 191 million shares [1] Group 2 - As of now, southbound funds hold 1.957 billion shares of Alibaba Health (00241.HK), accounting for 12.08% of the company's total issued ordinary shares [1] - Alibaba Health Information Technology Co., Ltd. is a holding company providing industrial internet solutions for the medical and pharmaceutical industry, serving as Alibaba Group's flagship platform in the health sector [1] - The company primarily engages in the sales of pharmaceutical health products, operates a pharmaceutical e-commerce platform, and offers consumer healthcare services, utilizing technologies such as cloud computing and big data for traceability and digital healthcare [1]

◎记者 马嘉悦 "中东、新加坡、欧洲……近一年我频繁飞国外，因为那里有大量配置中国资产的需求。"一位百亿级量 化私募创始人的经历，在私募业颇具代表性。 据私募排排网统计，截至2月9日，当前持有香港9号牌照的内地私募证券投资基金管理人已超130家，较 去年同期增加逾40家。与此同时，多家私募创始人在开年以来与外资的交流中，感受到全球资金增配中 国的意愿逐步增强。 用业内人士的话来说，私募出海从来不仅是扩圈，更是全球资本版图重构下的顺势而为。在这场浪潮 中，中国私募将进一步积聚站在全球舞台的力量。 私募出海趋势已成 135家，是持有香港9号牌照的内地私募证券投资基金管理人最新数字，也是迄今为止的最高数字。 私募排排网最新数据显示，截至2026年2月9日，当前持有香港9号牌照的内地私募证券投资基金管理 人，较去年同期增加了41家。其中，规模在50亿元以上的私募数量达62家，是私募出海的主力军。 "这些年去香港拿9号牌的私募越来越多，有的已经耕耘海外业务多年初见规模，有的则是为了公司未来 的全球规划做准备。"沪上某业内人士感慨称。 灵均投资透露，公司已在香港和新加坡分别设立办公室，作为出海的"桥头堡"，面向境外合格投 ...

来源：新浪基金 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调近两个季度，长期看，较多优质标的估值性价 比明显，当前位置建议加大关注。* 再来看港股通医疗板块表现，AI医疗、脑机接口概念股较为活跃，大权重领衔涨势，京东健康、阿里 健康、平安好医生齐涨3%左右，港股通医疗ETF华宝（159137）日线五连阳。 目前AI医疗在C端的渗透正在加速，从智能问诊到慢病管理的应用场景不断拓展，推动阿里健康、京东 健康等港股互联网医疗平台价值重估。 中信建投证券指出，港股器械整体创新属性较强，部分企业的创新产品具有license-out或被并购的可 能。基本面维度，行业内部多数公司经营业绩持续改善，低估值投资价值凸显。事件方面，预计迈瑞医 疗、可孚医疗今年将在港股上市，港股医疗器械板块效应和投资机会或将增多。* 2月9日，港股市场全面反弹，港股医药板块延续修复行情。 信达生物拿下88.5亿美元BD大单，无意外全天领涨，最高涨至8.55%，收涨7.42%，龙头股大受提振， 百济神州涨超3%，石药集团、中国生物制药、三生制药集 ...

2月9日，港股市场全面反弹，港股医药板块延续修复行情。 信达生物拿下88.5亿美元BD大单，无意外全天领涨，最高涨至8.55%，收涨7.42%，龙头股大受提振， 百济神州涨超3%，石药集团、中国生物制药、三生制药集体跟涨。 100%创新药研发标的——港股通创新药ETF（520880）高开后上探2.75%，收涨1.77%成功连阳，一并 站上10日均线，全天成交3.81亿元。 2月8日晚，信达生物公告，公司与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研 发进程。信达将获3.5亿美元首付款，最高可获85亿美元里程碑付款及大中华区以外净销售额梯度分 成。 2025年中国创新药License-out总交易规模达到创纪录的1357亿美元，2026年开年以来重磅合作频出，除 信达外，1月份石药-阿斯利康（185亿美元）、荣昌-艾伯维（56亿美元）两笔超级BD均充分验证国产 创新药管线的全球价值。 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调近两个季度，长期看，较多优质标的估值性价 比明显，当前位置建议加大 ...

研究报告 Research Report 9 Feb 2026 香港医疗 Hong Kong Health Care 医药行业周报（2026.02.02-2026.02.06）：市场情绪回暖；看好基本面表现强劲的创新药产业链龙头 Healthcare Weekly (2026.02.02-2026.02.06): Market Sentiment Warms; Bullish on Leaders in Innovative Drug Chain with Strong Fundamentals [Table_yemei1] 观点聚焦 Investment Focus | [Table_Info] | | | | | --- | --- | --- | --- | | 股票名称 | 评级 | 股票名称 | 评级 | | 百济神州 | Outperform 华润医药 | | Outperform | | 京东健康 | Outperform 国药控股 | | Neutral | | 药明生物 | Outperform 映恩生物 | | Outperform | | 信达生物 | Outperform 金斯瑞生物科 ...